Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TranspoCART19 |
| Synonyms | |
| Therapy Description |
TranspoCART19 is a transposon-based chimeric antigen receptor (CAR) T-cell therapy targeting CD19 that contains TNFRSF9 (4-1BB) and CD3zeta endodomains fused to a truncated human epidermal growth factor receptor (hEGFRt) as a safety switch, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 40034423). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TranspoCART19 | Transpo-CART19|Transpo CART19 | CD19 Immune Cell Therapy 72 | TranspoCART19 is a transposon-based chimeric antigen receptor (CAR) T-cell therapy targeting CD19 that contains TNFRSF9 (4-1BB) and CD3zeta endodomains fused to a truncated human epidermal growth factor receptor (hEGFRt) as a safety switch, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 40034423). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |